SavedAdd your journal

Journals / Caucasian Journal of Science / 2022 / Cilt: 9 - Sayı: 1

Biological properties of a newly isolated bacteriophage (NL1) that infects Escherichia coli O157:H7 strain

Neslihan MUTLU
Evren KOÇ
Özkan ÖZDEN
Pages
65–74
Publication Date
2022-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results showed that bacteriophage NL1 completely lysed the E.coli O157:H7 (RSKK 09007) and E.coli O:164 RSKK 324.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Escherichia coli O157: H7 strain was used as the standard strain for bacteriophages isolated from polluted environmental foci and animal waste-contaminated waters, and some of the enteroinvasive Escherichia coli strains previously isolated from sporadic cases were used to determine the host diversity of phages.
📊
Key Findings & Data:The physiological properties of bacteriophages specific to Escherichia coli O157:H7, designated Escherichiaphage NL1, were studied.
💡
Conclusion & Impact:Results showed that bacteriophage NL1 completely lysed the E.coli O157:H7 (RSKK 09007) and E.coli O:164 RSKK 324.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Esherichia coli O157:H7 · bacteriophages · resistance

Abstract

Escherichia coli O157: H7 strain was used as the standard strain for bacteriophages isolated from polluted environmental foci and animal waste-contaminated waters, and some of the enteroinvasive Escherichia coli strains previously isolated from sporadic cases were used to determine the host diversity of phages. The physiological properties of bacteriophages specific to Escherichia coli O157:H7, designated Escherichiaphage NL1, were studied. After the isolation step, bacteriophages were purified and their titer was increased. Cross-antigenic properties of the hosts were investigated with Escherichia phage NL1 phage. One-step growth curve parameters such as adsorption time of phages, latent period, burst size, multiplicity of infection value (MOI) were determined. Results showed that bacteriophage NL1 completely lysed the E.coli O157:H7 (RSKK 09007) and E.coli O:164 RSKK 324. In the study, the effects of phage NL1 only on E.coli O157:H7 were investigated. The calculated highest titer was determined as Optimal multiplycity of infection (2.16x108). It was determined that the latent period lasted for 20 minutes and the phage was reached the burst size at approximately 90 minutes.

🔖

Cite This Article

MUTLU, N., KOÇ, E., ÖZDEN, Ö. (2022). Biological properties of a newly isolated bacteriophage (NL1) that infects Escherichia coli O157:H7 strain. Caucasian Journal of Science, Cilt: 9 - Sayı: 1, 65–74. https://ajindex.com/articles/746143

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Alves, D.R., Gaudion, A., Bean, J.E., Perez, E. P., Arnot, T.C., Harper, D.R., Kot, W., Hansen, L.H., Enright, M.C., Jenkins, A.T. (2014). Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation. Appl. Environ. Microbiol., 80(21), 6694-703. https://doi.org/10.1128/AEM.01789-14
  2. Bhan, M.K., Mahalanabis, D., Fontaine, O., Pierce, N.F. (1994). Clinical trials of improved oral rehydration salt formulations: a review. Bull World Health Organ, 72(6), 945-55. PMID: 7867142; PMCID: PMC2486731. Boyd, E. F., Brüssow, H. (2002). Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends in Microbiology,10 (11), 521-9. https://doi.org/10.1016/S0966-842X(02)02459-9
  3. Bruttin, A., Brüssow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents. Chemother., 49 (7), 2874-8. https://doi.org/10.1128/AAC.49.7.2874-2878.2005
  4. Chibani-Chennoufi, S., Bruttin, A., Dillmann, M. L., Brüssow, H. (2004). Phage-host interaction: an ecological perspective. J. Bacteriol., 186, 3677–3686. https://doi.org/10.1128/JB.186.12.3677-3686.2004
  5. Chkonia, I., et al. (2012). Antibacterial-antifungal natural composite for dental use. Bacteriophages and Probiotics-Alternative to Antibiotics Cogress, July 1-4,
  6. Tbilisi, Georgia. Clokie, M.R.J., Kropinski, A.M. (2009). Bacteriophages Methods and Protocols. Springer Protocols. Humana Press.
  7. New York, USA. Donjacour, A., Paros, M. (2012). Bacterophage prevention and therapy for coliform mastisis. Bacteriophages and Probiotics-Alternative to Antibiotics Cogress, July 1-4,
  8. Tbilisi, Georgia. Donlan, R.M. (2009). Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol., 17(2), 66-72. https://doi.org/10.1016/j.tim.2008.11.002
  9. Endersen, E., et al. (2012). Isolation and characterization of six novel Mycobacteriophages and ınvestigation of their antimicrobial potential in milk. Bacteriophages and Probiotics- Alternative to Antibiotics Cogress, July 1-4,Tbilisi, Georgia. Goodridge, L., Gallaccio, A., Griffiths, M. W. (2003). Morphological, host range, and genetic characterization of two coliphages. Appl. Environ. Microbiol., 69, 5364–5371. https://doi.org/10.1128/AEM.69.9.5364-5371.2003
  10. Kim, J. W., Kathariou, S. (2009). Temperature-dependent phage resistance in Listeria monocytogenes epidemic clone II strains. An. Soc. Microbiol., 75 (8), 2433-2438. https://